Glenmark Pharmaceuticals posted muted revenues and a steep fall in profits for the first quarter of FY26, reflecting weak performance in key international markets even as domestic sales inched forward.
The Mumbai-based drugmaker reported consolidated revenues of ₹3,264 crore for April-June, broadly unchanged from ₹3,244 crore in the same period last year. However, net profit dropped 86 percent year-on-year to ₹47 crore, compared to ₹340 crore in Q1 FY25. Operating earnings also softened, with EBITDA down 1.3 percent at ₹580 crore, translating into a margin of 17.8 percent.
According to The Economic Times, regional performance highlighted pressure in Glenmark’s overseas businesses. Sales in Europe declined 4 percent to ₹667 crore, while North America dipped marginally by 0.4 percent to ₹778 crore. Domestic operations, by contrast, grew 3.7 percent to ₹1,239 crore, and emerging markets registered a flat 0.2 percent increase to ₹572 crore. The modest pickup in India and select developing geographies was not sufficient to offset the drag from Western markets.
Glenn Saldanha, Chairman and Managing Director of Glenmark, noted that the U.S. business had shown sequential growth on the back of new injectable and partnered product launches. He added that Europe and emerging markets had recorded compound annual growth rates of less than 25 percent and 10 percent respectively over the past three years, with expectations of stronger momentum from Q2 onward.
Beyond quarterly earnings, the company marked a significant milestone through its innovation subsidiary Ichnos Glenmark (IGI). In July, IGI signed a global licensing deal with AbbVie for its experimental trispecific antibody candidate ISB 2001, designed for cancer therapy. The agreement, valued at up to $1.9 billion, includes an upfront payment of $700 million (approximately ₹6,000 crore) and potential milestone payments of $1.225 billion (around ₹10,000 crore).
Analysts have highlighted the AbbVie transaction as a key positive for Glenmark’s financial outlook. S&P Global Ratings estimated that the deal could turn the company cash positive, from a net debt position of ₹490 crore earlier this year. Saldanha described the agreement as a validation of Glenmark’s innovation strategy, underscoring its focus on branded, specialty, and novel products to deliver sustainable value.
For industry stakeholders, Glenmark’s results highlight both the volatility of generic-driven international markets and the growing importance of innovation-led partnerships in securing long-term competitiveness.
